Veteran Healthcare Executive and Reimbursement Expert Joins InterVenn Biosciences’ Board of Advisors
SAN FRANCISCO--(BUSINESS WIRE)--InterVenn Biosciences, a clinical technology company leveraging AI-powered glycoproteomics to transform the future of healthcare, today announced that James Almas, MD, has joined the company’s Board of Advisors. Dr. Almas, who is VP & National Medical Director of Clinical Effectiveness at Laboratory Corporation of America Holding (Labcorp), is...
